Trusted Resources: Evidence & Education
Scientific literature and patient education texts
A Validated Measure of Adherence to Antibiotic Prophylaxis in Children With Sickle Cell Disease
source: Patient Prefer Adherence
year: 2016
authors: Natalie A Duncan, William G Kronenberger, Kisha C Hampton, Ellen M Bloom, Angeli G Rampersad, Christopher P Roberson, Amy D Shapiro
summary/abstract:Antibiotic prophylaxis is a mainstay in sickle cell disease management. However, adherence is estimated at only 66%. This study aimed to develop and validate a Sickle Cell Antibiotic Adherence Level Evaluation (SCAALE) to promote systematic and detailed adherence evaluation.
Methods:
A 28-item questionnaire was created, covering seven adherence areas. General Adherence Ratings from the parent and one health care provider and medication possession ratios were obtained as validation measures.
Results:
Internal consistency was very good to excellent for the total SCAALE (α=0.89) and four of the seven subscales. Correlations between SCAALE scores and validation measures were strong for the total SCAALE and five of the seven subscales.
Conclusion:
The SCAALE provides a detailed, quantitative, multidimensional, and global measurement of adherence and can promote clinical care and research.
organization: Indiana University School of Medicine, USADOI: 10.2147/PPA.S103874
read more
Related Content
-
Association of Antibiotic Choice With Hospital Length of Stay and Risk Factors for Readmission in Patients With Sick...Study objective: We determine the assoc...
-
Antibiotic prophylaxis for children with sickle cell anemiaBACKGROUND: Children with sickle cell an...
-
Kids Who Need Sickle Cell Meds Don’t Always Get ThemLess than a fifth of U.S. children with ...
-
A Conversation on Hydroxyurea: Insights and Information for the Sickle Cell Communityhttps://www.youtube.com/watch?v=Y6fmJn-5...
-
MARAC Advisory Statement: Monoclonal Antibodies Against SARS-CoV-2August 26, 2021 – The Sickle Cell Dis...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
-
ADDMEDICA receives FDA-approval for orphan drug Siklos®, first and sole hydroxyurea-based treatment for paediatric ...ADDMEDICA has announced that the...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.